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Abstract. Radiation therapy is one of the most promising 
therapeutic strategies in unresectable esophageal squamous 
cell carcinoma (ESCC). The histone deacetylase (HDAC) 
inhibitor has been shown to enhance radiosensitivity. 
Valproic acid (VPA) is a well-known drug used to treat 
seizure disorders and epilepsy, and has been shown to inhibit 
HDACs. We recently reported that a clinically safe dose of 
VPA enhances radiation-induced cytotoxicity in human ESCC 
cells. However, the mechanism of radiosensitizing effect of 
VPA has not yet been confirmed. The present study examined 
the effect of VPA on DNA double-strand break (DSB) repair 
after radiation in the human ESCC cell lines KES, TE9 and 
TE11 by examining H2AX phosphorylation (γH2AX) levels 
as a marker of radiation-induced DSBs. The present study also 
examined whether VPA inhibited radiation-induced DNA DSB 
repair by suppressing non-homologous end joining (NHEJ), 
focusing particularly on the acetylation of Ku70. VPA was 
shown to prolong γH2AX levels after irradiation in all three 
ESCC cell lines. Moreover, prolonged γH2AX foci formation 
after irradiation was also observed by immunocytochemistry 
following VPA pretreatment in KES and TE9 cells. VPA was 
shown to induce Ku70 acetylation after irradiation in all three 
ESCC cell lines. Our results suggest that VPA prolonged 
radiation-induced DSBs by inhibiting NHEJ in DSB repair 
pathways in ESCC. VPA could therefore be used as an effective 
radiosensitizer in ESCC radiotherapy.
Introduction
Esophageal squamous cell carcinoma (ESCC) is a malignant 
disease with a poor prognosis. The standard treatment for 
advanced ESCC patients has been surgical resection, although 
patients with unresectable ESCC are usually treated by defini-
tive chemoradiotherapy (CRT) (1). Various anticancer agents 
have been used to enhance the therapeutic effects of radio-
therapy (2-4), including cisplatin and 5-fluorouracil (2,5,6). 
Although favorable outcomes after CRT compared with radia-
tion therapy alone have been reported (1,7), adverse events are 
also noted, such as pulmonary dysfunction, leukocytopenia, 
radiation pneumonitis, pericardial effusion, pleural effusion, 
perforation and stenosis (8,9). Thus, there is a need to both 
enhance therapeutic effects and reduce radiation-induced 
adverse events when performing CRT for esophageal cancer.
Histone acetyltransferases (HATs) and histone deacety-
lases (HDACs) regulate the acetylation and deacetylation 
of histones, respectively. Core histone acetylation relaxes 
the chromatin structure and facilitates transcription (10,11). 
HDACs are involved in the deacetylation of chromatin histone 
proteins as well as non-histone proteins, which regulate cell 
differentiation, apoptosis and growth arrest (12,13). HDAC 
inhibitors act additively or synergistically with conventional 
cancer therapies such as radiotherapy, and numerous studies 
have shown that they enhance the radiation sensitivity of 
various cancer cell lines both in vitro and in vivo (14-23). 
These effects have been explained as the modulation of cell 
cycle regulation, particularly G1-phase arrest, the inhibition 
of DNA synthesis, the suppression of DNA repair pathways, 
apoptosis and the alteration of chromatin structures by histone 
hyperacetylation (16,19,20,24).
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Much attention has been given to the suppression of the 
double-strand break (DSB) repair pathway by HDAC inhibi-
tors, which enhance the radiation sensitivity and accumulation 
of the sensitive marker of DSBs, H2AX phosphorylation 
(γH2AX) (19). Homologous recombination (HR) and non-
homologous end joining (NHEJ) are the main pathways by 
which radiation-induced DSBs are repaired (25-27). Rad51 
is a key protein of HR, while NHEJ involves the Ku70/Ku86 
heterodimer which binds with strong affinity to broken DNA 
ends, and recruits the catalytic subunit of DNA-dependent 
protein kinases (DNA-PKcs). Ku70 functions are regulated 
by HATs and HDACs, and an increase in Ku70 expression 
in cancer cells was found to enhance the DNA DSB repair 
ability and reduce Bax-mediated apoptosis (28). Ku70 is also 
a target of some class I, II and III HDACs (29), while the use 
of HDAC inhibitors led to increased Ku70 acetylation accom-
panied by a reduced DNA binding affinity, with no disruption 
to Ku70/Ku80 heterodimer formation (30). Treatment of a 
myelogenous leukemia cell line with HDAC inhibitors before 
irradiation resulted in increased and prolonged expression of 
γH2AX repair foci (24).
Valproic acid (VPA), an 8-carbon branched-chain fatty 
acid, has a well-established efficacy for the treatment of 
epilepsy and other seizure disorders. VPA was also shown to 
be an effective inhibitor of HDACs (31,32), and to enhance 
radiosensitivity in various cancer cell lines (18,33-35). We 
recently reported a clinically safe dose of VPA that can 
enhance radiation-induced cytotoxicity in human ESCC 
cells by chromatin decondensation with histone hyperacety-
lation and the downregulation of Rad51 (36). For certain 
HDAC inhibitors, the acetylation of proteins in NHEJ 
has been demonstrated to be involved in the inhibition of 
radiation-induced DSBs repair (37). However, the mechanism 
underlying the inhibitory effect of VPA with respect to NHEJ 
in esophageal cancer has not yet been confirmed. The present 
study therefore examined whether VPA inhibits radiation-
induced DNA DSB repair by suppressing NHEJ in human 
ESCC cells, focusing particularly on the acetylation of Ku70 
by VPA.
Materials and methods
Cell lines and cell culture. Three human ESCC cell lines were 
used in the present study. The poorly differentiated ESCC 
cell line TE9, and the moderately differentiated TE11 cells 
were provided by Dr Tetsuro Nishihira (Higashimatsuyama 
Medical Association Hospital, Saitama, Japan). The highly 
differentiated ESCC cell line KES was established in our 
laboratory from endoscopic biopsy specimens obtained from a 
patient carrying highly differentiated ESCC. These cells were 
seeded in 75-cm2 dishes (Becton-Dickinson, Tokyo, Japan) 
and cultured in 10 ml of medium consisted of RPMI-1640 
(Gibco®, Life Technologies Corp., Tokyo, Japan) supplemented 
with 10% heat-inactivated fetal bovine serum (Nichirei 
Biosciences, Inc., Tokyo, Japan), 100 IU/ml penicillin and 
100 µg/ml streptomycin (Life Technologies Corp.) at 37˚C 
in a humidified atmosphere of 5% CO2. Cells were grown to 
confluency and harvested by trypsinization with 0.25 mg/ml 
trypsin/EDTA (Life Technologies Corp.), then resuspended in 
culture medium before use.
Reagents and antibodies. VPA was purchased from Sigma-
Aldrich Co. (Tokyo, Japan). Rabbit anti-phospho-histone 
H2AX (Ser 139) (γH2AX) (cat. #9718) and anti-acetylated-
lysine monoclonal antibodies (cat. #9814) were obtained from 
Cell Signaling Technology Co. Ltd. (Tokyo, Japan). Rabbit 
monoclonal anti-Ku70 antibody was purchased from Abcam 
(cat. #ab92450; Cambridge, UK), and goat anti-rabbit IgG 
horseradish peroxidase (HRP)-conjugated were purchased 
from Cell Signaling Technology (cat. #7074). β-actin and 
TATA-binding protein (TBP) were detected as control proteins 
using rabbit polyclonal anti-β-actin antibody (cat. #4967) and 
rabbit polyclonal anti-TBP antibody (cat. #8515) (both from 
Cell Signaling Technology), respectively.
Irradiation. Cells were irradiated by MBR-1520R-3 (Hitachi 
Medicotechnology, Hitachi, Japan) at a dose rate of 1 Gy/min. 
The X ray-irradiation power output was 125 kV, 20 mA. 
Forward-scattered radiation was filtered using a 0.5 mm Al 
and 0.2 mm Cu filter.
Immunofluorescent cytochemistry. Cells were cultured on 
Lab-Tec chamber slides (Nalge Nunc International, Rochester, 
NY, USA), treated with or without VPA (0.5 mM) for 24 h, 
then irradiated (6 Gy). Treated cells were fixed in methanol 
and acetone (1:1) for 1 min after irradiation at designated time-
points (0/4/8 h). After washing in phosphate-buffered saline 
(PBS), the slides were immersed in methanol containing 0.3% 
H2O2 for 10 min, blocked with 3.3% normal goat serum in PBS, 
and incubated with the rabbit monoclonal anti-phospho-histone 
H2AX (Ser 139) antibody (1:200) at 4˚C overnight. Following 
three washes in PBS, slides were incubated with an anti-rabbit 
IgG antibody conjugated with Alexa Fluor® 594 (cat. #A11012; 
Molecular Probes/Invitrogen, Carlsbad, CA, USA) for 1 h 
at room temperature in the dark. Nuclei were stained with 
Hoechst 33258 for 5 min, and slides were observed under an 
immunofluorescence microscope (Olympus BX50/BX-FLA; 
Tokyo, Japan).
Quantification of γH2AX levels after irradiation. To assess 
changes in radiation-induced DNA DSB repair, we compared 
γH2AX levels in irradiated cells treated with or without 
VPA (0.5 mM) using western blotting. Cells treated with 
combination therapy were pre-treated with VPA for 24 h 
before irradiation. Cell lysates were collected after irradia-
tion at designated times (0/10/30 min/1/2/4/8 h). The protein 
concentration in each lysate was measured using the Pierce 
BCA protein assay kit (Thermo Fisher Scientific, Rockford, 
IL, USA). A sample volume equivalent to 20 µg protein 
from each lysate was loaded on a 10% polyacrylamide gel 
(Mini-Protean TGX Precast Gels; Bio-Rad Laboratories 
Inc., Berkeley, CA, USA) and separated by electrophoresis. 
Proteins were transferred to polyvinylidene difluoride (PVDF) 
membranes (Trans-Blot Turbo mini-PVDF Transfer Pack; 
Bio-Rad Laboratories Inc.), blocked with Tris-buffered saline 
with Tween-20 Tablets, pH 7.6 (Takara Bio, Inc., Shiga, Japan), 
then incubated with the rabbit monoclonal anti-phospho-
histone H2AX (Ser 139) primary antibody at a 1:1,000 dilution 
for 10 min at room temperature. A rabbit polyclonal β-actin 
antibody at 1:5,000 dilution was used to detect β-actin as a 
control protein. Secondary antibody incubation using goat 
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anti-rabbit IgG HRP-conjugated at a 1:4,000 dilution was 
carried out according to the manufacturer's instructions for 
10 min at room temperature (cat. SNAP2BASE; SNAP i.d. 2.0; 
Millipore, Billerica, MA, USA). Membranes were treated 
with PVDF Blocking Reagent for Can Get Signal® (Toyobo 
Co., Ltd., Osaka, Japan). The antibody-antigen complex was 
detected using enhanced chemiluminescence by an ECL 
western blotting detection kit (General Electric Healthcare 
Japan Co., Ltd., Tokyo, Japan) and the Light-Capture system 
(ATTO Co., Ltd., Tokyo, Japan). Quantification was performed 
by the CS analyzer program (ATTO Co., Ltd.) and normalized 
to β-actin levels.
Assessment of Ku70 acetylation. Cells were incubated with 
or without VPA (0.5 mM) for 24 h, then irradiated (6 Gy) 
and harvested promptly. Nuclear proteins were extracted 
using a Nuclear Extract kit (Active Motif, Tokyo, Japan), and 
protein concentrations were determined using a Pierce BCA 
protein assay kit as before. A rabbit monoclonal anti-Ku70 
antibody at 1:80 dilution was used for immunoprecipitation. 
Figure 1. Effects of VPA on radiation-induced DNA DSBs. ESCC cells KES, TE9 and TE11 were cultured with or without VPA (0.5 mM) for 24 h, then irradi-
ated (IR, 6 Gy). H2AX phosphorylation (γH2AX) levels, as a sensitive marker of radiation-induced DSBs, were determined by western blotting at designated 
times (0/10/30 min/1/2/4/8 h). β-actin was used as a loading control in each blot. VPA, valproic acid; DSBs, DNA double-strand breaks; ESCC, esophageal 
squamous cell carcinoma.
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Magnetic beads (Dynabeads® Protein G Immunoprecipitation 
kit; Life Technologies, Carlsbad, CA, USA) were used for 
immunoprecipitation of the target antigen according to the 
manufacturer's instructions. The target antibody was incu-
bated with Dynabeads® with rotation for 10 min to enable 
binding to occur. After adding the extracted nuclear protein 
to the beads-antibody complex, the sample was incubated 
at 4˚C overnight with rotation to form an antigen-beads-
antibody complex. The target antigen was dissociated from 
the beads-antibody complex with elution buffer. Ku70 acety-
lation was then examined by western blotting using a rabbit 
monoclonal anti-acetylated-lysine primary antibody at a 1:300 
dilution. To detect TBP as a control nuclear protein, a rabbit 
polyclonal anti-TBP antibody (Cell Signaling Technology) at 
1:300 dilution was used. Goat anti-rabbit IgG-HRP conjugates 
at 1:4,000 dilution were used as secondary antibodies.
Results
Changes of radiation-induced γH2AX levels by VPA. γH2AX 
levels in cells pre-treated with VPA were higher than in 
untreated cells in all three ESCC cell lines (Fig. 1). γH2AX 
levels were detected by western blotting and quantified by 
measuring the ratio of γH2AX to β-actin. The time course 
of γH2AX is displayed in Fig. 2. VPA was shown to prolong 
γH2AX levels after irradiation in all three ESCC cell lines. 
Moreover, prolonged γH2AX foci formation after irradiation 
was also observed by immunocytochemistry following VPA 
pretreatment in KES and TE9 cells (Fig. 3).
Acetylation of Ku70 by VPA. The acetylation of Ku70 by VPA 
was estimated by western blotting following immunoprecipi-
tation of the nuclear extract with an anti-Ku70 antibody and 
the detection of acetylated-lysine. In all three ESCC cell lines, 
increased Ku70 acetylation after irradiation was observed 
following pretreatment with 0.5 mM VPA for 24 h (Fig. 4).
Discussion
In the present study, we showed that VPA inhibited the 
radiation-induced DNA DSB repair in ESCC cell lines, and 
that this was accompanied by acetylation of the DSB repair 
protein, Ku70.
Previously, γH2AX has been described as a highly sensitive 
method to detect irradiation-induced DSBs (38,39). In response 
to this, serine 139 within the conserved C-terminal region of 
the H2AX protein becomes phosphorylated by one of the DNA 
damage signaling kinases of the phosphatidylinositol-3-OH-
Figure 2. Time course of the H2AX phosphorylation level changes after irradiation. γH2AX levels were detected by western blotting in KES, TE11 and TE9 
cells cultured with (filled squares) or without (filled triangles) VPA, and were then irradiated. Values were quantified by measuring contrasting densities and 
calculated as the ratio of γH2AX to β-actin. VPA, valproic acid.
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Figure 3. Changes over time in the H2AX phosphorylation foci formation after irradiation, as assessed by immunofluorescent cytochemistry. Micrographs of 
γH2AX foci (red) in nuclei (blue) of KES and TE9 cells pre-treated with or without VPA (0.5 mM) for 24 h were obtained (0 h/4 h/8 h) after irradiation (IR). 
VPA was shown to prolong γH2AX foci formation after irradiation. Scale bar, 10 µm. VPA, valproic acid.
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kinase-like family. This phosphorylation rapidly spreads to a 
region of chromatin surrounding the DSBs, resulting in the 
formation of γH2AX foci. The main role of H2AX phos-
phorylation in the DNA damage response was reported to be 
the recruitment of DNA repair proteins to DSB sites and the 
preparation of a platform for signaling and repair (38,40). In 
the present study, we analyzed H2AX phosphorylation levels 
by western blotting, and examined γH2AX foci by immunocy-
tochemistry as a marker of DNA DSB after irradiation.
More than 18 mammalian HDAC enzymes (HDAC 1-11 
and sirtuins 1-7) have been identified, which are grouped into 
four classes according to their homology (41). HDAC inhibi-
tors are an emerging class of drugs that have shown promise 
as anticancer agents when used alone or in combination with 
conventional therapies (42,43). VPA has been used for the 
treatment of seizure disorders and epilepsy. Previous studies 
found that it induces apoptosis and the accumulation of hyper-
acetylated histones H3 and H4, and also inhibits class I HDACs 
(HDACs 1, 2 and 3) and class II subclass I HDACs (HDACs 4, 
5 and 7) (31,32,44,45). Therapeutic plasma concentrations used 
clinically for epilepsy treatment range from 50-100 µg/ml, 
which is equivalent to 0.3-0.6 mM. Therefore, 0.5 mM VPA is 
a clinically safe concentration (46) that we used in the present 
study based on our previous growth inhibition assay in which 
0.5 mM VPA did not inhibit the growth of ESCC cells (36).
We recently showed that VPA enhanced the radiosen-
sitizing effect by chromatin decondensation with histone 
hyperacetylation and downregulation of Rad51 (36). Various 
mechanisms are responsible for this VPA-mediated enhance-
ment in radiosensitivity. Firstly, HDAC inhibitors lead to 
the acetylation of histone tails, which induces reduction 
of the electrostatic charge interactions between DNA and 
histones, permitting access to the chromatin structure in asso-
ciation with chromatin decondensation (47,48). Additionally, 
Harikrishnan et al (49) reported that euchromatin was more 
sensitive to radiation-induced DSBs than heterochromatin, 
and that histone modifications contributed to the radiosensi-
tivity effects of HDAC inhibitors. Thus, they concluded that 
heterochromatin is more resistant to histone modification and 
DNA damage. Secondly, HDAC inhibitors inhibit the radia-
tion-induced DNA DSB repair process. In the present study, 
we confirmed that VPA prolonged radiation-induced DNA 
DSB repair by measuring γH2AX level changes overtime after 
irradiation. This lengthening of DNA DSBs can be attributed 
to the VPA-induced inhibition of the DSB repair process. 
While we previously found that Rad51 expression was down-
regulated by VPA, and Adimoolam et al (37) reported that 
suberoylanilide hydroxamic acid (PCI-24781) also suppressed 
Rad51 expression, the mechanism of its suppression by HDAC 
inhibitors has not been fully clarified. Further studies are 
therefore necessary to understand this.
The functional inhibition of non-histone proteins by 
HDAC inhibitors has recently been reported to involve acety-
lation (30). However, it is difficult to examine the acetylation 
of non-histone proteins by western blotting due to the lack 
of an appropriate primary antibody. Recent studies reported 
that the acetylation of non-histone proteins by HDAC 
inhibitors induced the functional inhibition of DNA repair 
activity (20,30). Furthermore, Chen et al (30) found that HDAC 
inhibitors reduced the DNA end-binding affinity of Ku70 by 
acetylation. In the present study, we focused on Ku70 as a key 
protein of NHEJ in the radiation-induced DNA DSB repair 
pathway. We confirmed that VPA increased Ku70 acetylation 
levels in three ESCC cell lines.
In DNA DSB repair pathways, ataxia telangiectasia 
mutated and ataxia telangiectasia related proteins are impor-
tant components of the DSB signaling cascade. Their activation 
results in the phosphorylation of downstream substrates, 
including p53 (50). HDACs can regulate the expression of 
various genes by direct interaction (13). For instance, p53 is 
downregulated by HDACs 1, 2 and 3 (35,51) and acetylated 
by VPA (45), which induces cell cycle regulation, apoptosis 
and inhibition of DNA DSB repair (45,50). Several proteins 
inhibit DNA DSBs repair pathways by mediating the resection 
process of DNA ends (52,53). Thus, VPA inhibits HR in the 
repair pathway by acetylating Sae2 and Exo1, which are two 
nucleases involved in resecting DNA ends (54). Our present 
findings and those of earlier studies showed that VPA has the 
potential to synergistically inhibit DNA DSB repair pathways 
by acetylating p53 in the DSB signaling cascade, nucleases 
involved in DNA end resection and Ku70 in NHEJ, as well 
as suppressing Rad51 expression levels in HR. VPA may 
Figure 4. Acetylation of Ku70 by VPA. Esophageal squamous cell carcinoma cell lines (KES, TE9 and TE11) were cultured with or without VPA (0.5 mM) 
for 24 h, then were irradiated (IR, 6 Gy). Nuclear proteins were extracted from the lysates. Ku70 was separated from the collected nuclear proteins by immu-
noprecipitation, and its acetylation analyzed by western blotting using an anti-acetylated lysine (Ac-Lys) antibody. TATA-binding protein (TBP) was used as 
the loading control in each blot. VPA, valproic acid.
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therefore be a suitable agent to combine with radiotherapy due 
to its multiple effects in DNA DSB repair inhibition. Further 
studies are needed to clarify the precise mechanisms of DNA 
DSB repair inhibition by VPA in ESCC.
Tomita et al observed a difference in the proportion of 
HR and NHEJ in DSB repair in chicken B lymphoid cell 
lines according to the irradiation dose rate. Although both 
HR and NHEJ were activated following high-dose irradiation 
(0.9 Gy/min), the activation of NHEJ dominated after low-dose 
irradiation (1.0 mGy/min) (55). This suggests that the inhibi-
tion of NHEJ may be a more effective means of enhancing 
radiosensitivity, regardless of the radiation dose. Moreover, 
Karagiannis and El-Osta (50) reported a radiation protection 
effect associated with HDAC inhibitors. These not only act 
as radiosensitizers in response to irradiation, but also reduce 
radiation-induced dermatitis and esophagitis by suppressing 
the expression of transforming growth factor-β and tumor 
necrosis factor-α. Therefore, the concomitant use of VPA with 
radiation therapy against esophageal cancer has the potential 
to reduce various radiation-induced adverse effects.
In conclusion, VPA treatment at clinically safe concentra-
tions enhances radiosensitivity by inhibiting both HR and 
NHEJ in the DNA DSB repair process, and prolonging DNA 
DSBs. Therefore, VPA has considerable potential as a thera-
peutic agent for esophageal cancer.
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